Medline Inc. (MDLN) Stock Forecast
MDLN analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.44 / 5 from 27 analysts
- Price target
- $44.42 average of analyst targets
- Upside to target
- +23.5% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $0.32
- 52-week range
- $31.64 – $49.99
MDLN analyst ratings
27 analystsNumber of analysts at each rating.
MDLN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MDLN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.35 | $0.28 | $0.47 | — | — | 23 |
| Current fiscal year (2026) | $1.54 | $1.36 | $1.82 | $1.32 | +17.0% | 19 |
| Next fiscal year (2027) | $1.58 | $1.40 | $1.83 | $1.54 | +2.0% | 25 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MDLN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $7.72B | $7.66B | $7.89B | — | 23 |
| Current fiscal year (2026) | $31.23B | $31.10B | $31.48B | +9.8% | 26 |
| Next fiscal year (2027) | $33.68B | $33.38B | $34.12B | +7.8% | 26 |
MDLN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MDLN revenue: reported and forecast
MDLN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.39 | $0.35 | $0.35 | $0.35 | $0.35 | −10.3% | 1 up · 2 down |
| Current fiscal year (2026) | $1.51 | $1.56 | $1.56 | $1.55 | $1.54 | +2.1% | 0 up · 2 down |
| Next fiscal year (2027) | $1.67 | $1.59 | $1.58 | $1.58 | $1.58 | −5.5% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MDLN earnings surprises
Reported EPS vs the consensus estimate for the last 4 quarters; MDLN beat in 4 of 4.
What analysts expect from MDLN
27 analysts cover Medline; their consensus rating is buy (4.44 on a 1–5 scale, where 5 is a strong buy). The average price target is $44.42, 23.5% above the latest close of $35.96. Analysts expect earnings of $1.54 per share for 2026, +17.0% from a year earlier. For 2027 the average estimate is $1.58 per share on revenue of $33.7 billion. Medline beat the EPS estimate in 4 of the last 4 quarters.
Related: MDLN income statement, MDLN key metrics, MDLN chart. See the MDLN stock overview for the latest quote and news.
MDLN forecast FAQ
What is Medline's price target?
The average analyst price target for Medline is $44.42, 23.5% above the latest close of $35.96.
Is Medline a buy, hold or sell?
Of 27 analysts covering Medline, 16 rate it a strong buy, 7 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Medline's EPS forecast?
Analysts forecast $1.54 per share for 2026 (range $1.36 to $1.82); for 2027 the estimate is $1.58.
What is Medline's revenue forecast?
The average revenue estimate for 2026 is $31.2 billion, growth of 9.8%; for 2027 it is $33.7 billion.
When does Medline report earnings?
Medline is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens; the EPS estimate is $0.32.
Does Medline usually beat earnings estimates?
Medline reported EPS at or above the analyst estimate in 4 of the last 4 quarters.